Assistant Professor, Department of Urology, UCSF
Additional Websites
Education
Dartmouth College, Hanover, NH, BA, 1991-95, English
Yale University, New Haven, CT, MD, MPH, 1995-00, Medicine, Health Policy
Professional Experience
- 2000-01
Internship in General Surgery (preliminary to Urology), Yale University, New Haven, CT
- 2001-03
Research Fellowship in Genitourinary Oncology, University of California, San Francisco, CA
- 2004-08
Residency in Urology, University of California, San Francisco, CA
- 2008-09
Clinical Fellow, Genitourinary Oncology, University of California, San Francisco, CA
- 2009-present
Assistant Professor, Department of Urology, University of California, San Francisco, CA
Honors & Awards
- 1995
College honors: summa cum laude, Phi Beta Kappa, high honors in major, Presidential Scholar, Rufus Choate Scholar, B. William Hochman Prize in American Literature - 1996
American Cancer Society Research Fellowship - 1999
AMA John Conley Ethics Essay Contest, honorable mention - 2003
UCSF Prostate Cancer Research Symposium, 2nd place, Clinical Research - 2004
UCSF Prostate, Breast, Prostate SPORE Scientific Retreat, honorable mention, Clinical Research - 2005
Northern California Urology Resident Research Symposium, 1st place, Clinical Research - 2006
Northern California Urology Resident Research Symposium, 3rd place, Clinical Research - 2007
AUA Gerald P. Murphy Prostate Scholar - 2007
Northern California Urology Resident Research Symposium, 2nd place, Clinical Research - 2007
Western Section AUA Miley B. Wesson Resident Essay Contest, 3rd place - 2008
Society of Urologic Oncology Poster Session, 3rd place overall - 2008
Western Section AUA Miley B. Wesson Resident Essay Contest, 3rd place - 2008
Western Section AUA Poster Session I, 1st place
Selected Publications
- Cooperberg MR. Re: Quality-of-life Effects of Prostate-specific Antigen Screening. Eur Urol. 2013 Jun; 63(6):1130.
View on PubMed - Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM. Limitations of Basing Screening Policies on Screening Trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care. 2013 Apr; 51(4):295-300.
View on PubMed - Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS, Swanson GP, Stone S, Carroll PR. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013 Apr 10; 31(11):1428-34.
View on PubMed - Blaschko SD, Weiss DA, Odisho AY, Greene KL, Cooperberg MR. Proximal bulbar periurethral abscess. Int Braz J Urol. 2013 Jan; 39(1):137-8.
View on PubMed - Cooperberg MR, Ramakrishna NR, Duff SB, Hughes KE, Sadownik S, Smith JA, Tewari AK. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int. 2013 Mar; 111(3):437-50.
View on PubMed - Cooperberg MR. Factors associated with treatment received by men diagnosed with prostate cancer in queensland, australia. BJU Int. 2012 Dec; 110(11 Pt B):E720.
View on PubMed - Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res. 2012 Oct 1; 18(19):5471-8.
View on PubMed - Porten SP, Cooperberg MR. High-risk nonmuscle invasive bladder cancer: definition and epidemiology. Curr Opin Urol. 2012 Sep; 22(5):385-9.
View on PubMed - Odisho AY, Berry AB, Ahmad AE, Cooperberg MR, Carroll PR, Konety BR. Reply to Jai Prakash, Apul Goel and Manish Garg's Letter to the Editor re: Anobel Y. Odisho, Anna B. Berry, Ardalan E. Ahmad, Matthew R. Cooperberg, Peter R. Carroll, Badrinath R. Konety. Reflex ImmunoCyt Testing for the Diagnosis of Bladder Cancer in Patients with Atypical Urine Cytology. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.04.019. Eur Urol. 2012 Nov; 62(5):e88.
View on PubMed - Glass AS, Cooperberg MR, Carroll PR. Early detection of prostate cancer: more information, more clarity. Eur Urol. 2012 Nov; 62(5):753-5; discussion 755-6.
View on PubMed - Cooperberg MR, Chan JM. Editorial comment. Urology. 2012 Aug; 80(2):305-6.
View on PubMed - Cooperberg MR. Will biomarkers save prostate cancer screening? Eur Urol. 2012 Dec; 62(6):962-3.
View on PubMed - Kutikov A, Cooperberg MR, Paciorek AT, Uzzo RG, Carroll PR, Boorjian SA. Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. Prostate Cancer Prostatic Dis. 2012 Dec; 15(4):374-9.
View on PubMed - Dall'era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012 Dec; 62(6):976-83.
View on PubMed - Reese AC, Cowan JE, Brajtbord JS, Harris CR, Carroll PR, Cooperberg MR. The quantitative Gleason score improves prostate cancer risk assessment. Cancer. 2012 Dec 15; 118(24):6046-54.
View on PubMed - Cooperberg MR. Urological cancer: For localized prostate cancer, does technology equal progress? Nat Rev Clin Oncol. 2012 Jul; 9(7):371-2.
View on PubMed - Cooperberg MR. To predict the future, consider the present as well as the past. Eur Urol. 2012 Jul; 62(1):53-4.
View on PubMed - Odisho AY, Berry AB, Ahmad AE, Cooperberg MR, Carroll PR, Konety BR. Reflex ImmunoCyt Testing for the Diagnosis of Bladder Cancer in Patients with Atypical Urine Cytology. Eur Urol. 2013 May; 63(5):936-40.
View on PubMed - Cooperberg MR. Thwarting high-risk prostate cancer: the right treatments for the right patients. Eur Urol. 2012 Jun; 61(6):1107-9.
View on PubMed - Aaronson DS, Odisho AY, Hills N, Cress R, Carroll PR, Dudley RA, Cooperberg MR. Proton beam therapy and treatment for localized prostate cancer: if you build it, they will come. Arch Intern Med. 2012 Feb 13; 172(3):280-3.
View on PubMed
View on UCSF Profiles
